SSA packs a power punch with its maiden workshop on Pharma QbD

SSA Business Solutions recently concluded a 4-day intensive workshop on Pharma Quality by Design (QbD) and added a brand new feather to its already colourful hat. What makes this accomplishment special is the overwhelming response SSA garnered from its participants and their heartfelt appreciation of SSA’s understanding of this complex subject and its execution capabilities. And what makes this achievement perhaps even sweeter is the fact that SSA is the only company in India to offer such an intensive hands-on workshop on QbD.

Come January 2013 and QbD is all set to become a mandate for all the pharmaceuticals. There is strong pressure to develop innovative medicines for unmet medical needs at affordable prices to patients and payers. The pharmaceutical industry is highly regulated by international regulatory agencies that have set very high quality and efficacy conformance standards of medicinal products. There is no doubt that QbD will increase the quality of medicinal products and conserve industry resources. SSA was bang on its money at assessing this need of the industry and developing this course.

Needless to say was a huge success. Very senior decision makers from companies like USV, Sun Pharma, and Wockhardt actively participated. The Knowledge Management team of SSA developed a terrific curriculum after thoroughly assessing the market needs and requirements.

Mr. Vijay Dhonde, Sr. VP – Operations, SSA, along with SSA’s senior associates and Subject Matter Experts like Dr. K V Gopala Krishna and Mr. Ranjit Barshikar were the lead trainers. Together they brought their years of experience to the table and made this a highly interactive and hands-on workshop.

With this, SSA looks poised to launch this workshop across cities and share the learning with as many pharmaceutical companies as possible. Kudos to the team!

Here is the verbatim feedback of the participants:

• Excellent.
  Serving Solution to most of my expectations.
• Journey of QbD was satisfactory.
  Most of the terminology well explained for the non staticians.
• Excellent, need to discuss some of the critical observations by EU/MHRA & 483’s, warning letters by US FDA auditors to understand and criticality to relevant topics. (Eg. Related to risk assessment, product failure, critical parameter etc.)
• Excellent.
  Got clear view and knowledge on QbD. The content and workshop is excellent.
• Excellent.
  It will help us to focus on our target of applying QbD as per expectation of FDA.
• Excellent Workshop
• Got the basics of QbD. Understood various DOE designs
• It gave adequate knowledge about the subject

And here is a picture. Take a look.